United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

United Therapeutics has reported Asset Writedowns and Impairment for 5 years, with the latest figure at -$5.3 million in Q4 2022.

• Quarterly Asset Writedowns and Impairment rose 94.37% year-over-year to -$5.3 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$5.3 million (up 94.27% YoY) and the FY2025 annual result came in at $21.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to -$5.3 million in Q4 2022 per UTHR's latest filing, from $1.7 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $6.1 million in Q1 2021 and troughed at -$94.2 million in Q4 2021.
• A 4-year average of -$11.6 million and a median of $650000.0 in 2019 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2020 and 2022: Asset Writedowns and Impairment surged 1450.0% in 2020, then plunged 72.13% in 2022.
• Over 4 years, Asset Writedowns and Impairment stood at -$8.4 million in 2019, then surged by 164.29% to $5.4 million in 2020, then slumped by 1844.44% to -$94.2 million in 2021, then soared by 94.37% to -$5.3 million in 2022.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$5.3 million, $1.7 million, and -$94.2 million for Q4 2022, Q1 2022, and Q4 2021 respectively.